From: Feasibility of outpatient daycase local anaesthestic Rezūm™ without sedation
Median age (IQR) | 66 (64–71) |
---|---|
Pre-operative (13 patients) | |
Mean prostate size | 61.2 cc |
Mean PSA | 2.3 |
Medications for LUTS | |
Alpha blocker | 8(61.5%) |
5 alpha reductase inhibitor | 7 (53.9%) |
Anticholinergic | 3 (23.1%) |
Phosphodiesterase 5 inhibitor | 0 |
Mirabegron | 0 |
Not on any medications | 2 (15.4%) |
Pre-op catheter use | 1 long term catheter for 1 year 1 intermittent self-catheter for 6 months |
Mean Pre-op IPSS | 20.6 |
Mean Pre-op QOL | 4.6 |
Mean Pre-op Qmax | 8.8 ml/s |
Mean Pre-op Av flow | 3.5 ml/s |
Median PVR | 63 (34–113) |
Operative (13 patients) | |
Number of treatments on each lobe | |
1 | 6 patients |
2 | 7 patients |
Mean pain score (0–10) | 2.1 |
Post-operative (7 patients followed up so far) | |
Successful TWOC | 13/13 (1 failed first TWOC) |
Immediate Complications | - 1 UTI (treated with oral antibiotics) |
Delayed complications | - 3 Bleeding (not requiring admission) - 3 retrograde ejaculation - 1 Erectile dysfunction |
Mean Post-op IPSS | 5.4 |
Mean Post-op QOL | 1.3 |
Mean Post-op Qmax | 14.4 ml/s |
Mean Post-op Average flow | 7.2 ml/s |
Median PVR (IQR) | 19 (1–40) |